Skip to main content
HR 5982 116th Congress House

Safe Medicine Act

Official title: To direct the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to… Show full official titleShow less

Official title: To direct the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination.

Introduced: March 2, 2020 See on congress.gov
Health Administrative law and regulatory proceduresAsiaChinaCongressional oversight
More subjectsShow fewer subjects
Drug safety, medical device, and laboratory regulationGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth technology, devices, suppliesManufacturingPrescription drugsPublic contracts and procurementTrade restrictions
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 26, 2020
Referred to the House Committee on Energy and Commerce.
Feb 26, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 26, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Safe Medicine Act

This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.

The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.

 Related & companion bills 1
  • HR 5927 Related bill Safe Medicine Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Republican 1
R
Fitzpatrick, Brian K.
Pennsylvania · Mar 2, 2020
Meadows, Mark
· Mar 2, 2020
RYAN, TIM
· Feb 26, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5982: Safe Medicine Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-5982/
MLA
"H.R. 5982: Safe Medicine Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-5982/.
Bluebook (legal)
H.R. 5982, 116th Cong. (2026), https://openamerica.io/bill/116-HR-5982/.
Markdown link
[H.R. 5982: Safe Medicine Act](https://openamerica.io/bill/116-HR-5982/)
Report a problem